お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、慢性特発性便秘（CIC）治療薬の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に慢性特発性便秘（CIC）治療薬市場を分類しています。
本レポートでは世界の慢性特発性便秘（CIC）治療薬市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Actavis、Chugai Pharmaceutical、Ferring International Center、Synergy Pharmaceuticals、Pfizer、GlaxoSmithKline、Roche Holding、Sanofi、Bayer、Salix Pharmaceuticals、Sucampo Pharmaceuticals、Ironwood Pharmaceuticals、Progenics Pharmaceuticals

レポートは慢性特発性便秘（CIC）治療薬の主要生産者を調査し、主要地域や国の消費状況も提供します。慢性特発性便秘（CIC）治療薬の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Lubiprostone
    Linaclotide
    Others

用途別の市場セグメント：
    Hospitals & Clinics
    Ambulatory Surgical Centres
    Long Term Care Centres
    Others

本レポートの詳細内容
本レポートは、世界の慢性特発性便秘（CIC）治療薬市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて慢性特発性便秘（CIC）治療薬市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）の慢性特発性便秘（CIC）治療薬生産量、成長率、市場シェアを調査している。

二. 消費面では、慢性特発性便秘（CIC）治療薬の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーの慢性特発性便秘（CIC）治療薬売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の慢性特発性便秘（CIC）治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本慢性特発性便秘（CIC）治療薬のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：慢性特発性便秘（CIC）治療薬のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： 慢性特発性便秘（CIC）治療薬の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおける慢性特発性便秘（CIC）治療薬の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章慢性特発性便秘（CIC）治療薬メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：慢性特発性便秘（CIC）治療薬の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：慢性特発性便秘（CIC）治療薬の主要メーカーの概要を提供し、製品の説明と仕様、慢性特発性便秘（CIC）治療薬の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：慢性特発性便秘（CIC）治療薬の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
The global Chronic Idiopathic Constipation (CIC) Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Chronic Idiopathic Constipation (CIC) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Chronic Idiopathic Constipation (CIC) Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Chronic Idiopathic Constipation (CIC) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chronic Idiopathic Constipation (CIC) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Chronic Idiopathic Constipation (CIC) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Chronic Idiopathic Constipation (CIC) Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi and Bayer, etc.

Market Segmentation
By Company
    Actavis
    Chugai Pharmaceutical
    Ferring International Center
    Synergy Pharmaceuticals
    Pfizer
    GlaxoSmithKline
    Roche Holding
    Sanofi
    Bayer
    Salix Pharmaceuticals
    Sucampo Pharmaceuticals
    Ironwood Pharmaceuticals
    Progenics Pharmaceuticals

Segment by Type
    Lubiprostone
    Linaclotide
    Others

Segment by Application
    Hospitals & Clinics
    Ambulatory Surgical Centres
    Long Term Care Centres
    Others

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Chronic Idiopathic Constipation (CIC) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Chronic Idiopathic Constipation (CIC) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Idiopathic Constipation (CIC) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of Lubiprostone
    Table 3. Major Manufacturers of Linaclotide
    Table 4. Major Manufacturers of Others
    Table 5. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 7. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 8. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 9. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region (2019-2024)
    Table 10. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region (2025-2030)
    Table 11. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 12. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2019-2024) & (K Units)
    Table 13. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2025-2030) & (K Units)
    Table 14. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2019-2024)
    Table 15. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2025-2030)
    Table 16. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers (2019-2024) & (K Units)
    Table 17. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Manufacturers (2019-2024)
    Table 18. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 19. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2019-2024)
    Table 20. Global Key Players of Chronic Idiopathic Constipation (CIC) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
    Table 21. Chronic Idiopathic Constipation (CIC) Drugs Price by Manufacturers 2019-2024 (USD/Unit)
    Table 22. Global Chronic Idiopathic Constipation (CIC) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Chronic Idiopathic Constipation (CIC) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Idiopathic Constipation (CIC) Drugs as of 2023)
    Table 24. Global Key Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Manufacturing Base Distribution and Headquarters
    Table 25. Global Key Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Product Offered and Application
    Table 26. Global Key Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, Date of Enter into This Industry
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 29. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 30. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Type (2019-2024)
    Table 31. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Type (2025-2030)
    Table 32. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 33. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 34. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Type (2019-2024)
    Table 35. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Type (2025-2030)
    Table 36. Chronic Idiopathic Constipation (CIC) Drugs Price by Type (2019-2024) & (USD/Unit)
    Table 37. Global Chronic Idiopathic Constipation (CIC) Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
    Table 38. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 39. Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 40. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Application (2019-2024)
    Table 41. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Application (2025-2030)
    Table 42. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 43. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 44. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Application (2019-2024)
    Table 45. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Application (2025-2030)
    Table 46. Chronic Idiopathic Constipation (CIC) Drugs Price by Application (2019-2024) & (USD/Unit)
    Table 47. Global Chronic Idiopathic Constipation (CIC) Drugs Price Forecast by Application (2025-2030) & (USD/Unit)
    Table 48. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 49. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 50. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 51. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 52. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 53. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 54. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 55. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 56. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 57. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 58. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 59. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2019-2024) & (K Units)
    Table 60. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2025-2030) & (K Units)
    Table 61. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 62. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 63. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 64. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 65. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 66. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 67. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 68. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 69. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 70. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 71. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 72. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2019-2024) & (K Units)
    Table 73. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2025-2030) & (K Units)
    Table 74. China Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 75. China Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 76. China Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 77. China Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 78. China Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 79. China Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 80. China Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 81. China Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 82. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 83. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 84. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 85. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 86. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 87. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 88. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 89. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 90. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 91. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2019-2024) & (US$ Million)
    Table 92. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue by Region (2025-2030) & (US$ Million)
    Table 93. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2019-2024) & (K Units)
    Table 94. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales by Region (2025-2030) & (K Units)
    Table 95. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2019-2024) & (K Units)
    Table 96. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Type (2025-2030) & (K Units)
    Table 97. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2019-2024) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Type (2025-2030) & (US$ Million)
    Table 99. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2019-2024) & (K Units)
    Table 100. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Application (2025-2030) & (K Units)
    Table 101. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2019-2024) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Application (2025-2030) & (US$ Million)
    Table 103. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 104. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2019-2024) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Country (2025-2030) & (US$ Million)
    Table 106. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2019-2024) & (K Units)
    Table 107. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales by Country (2025-2030) & (K Units)
    Table 108. Actavis Company Information
    Table 109. Actavis Description and Major Businesses
    Table 110. Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 111. Actavis Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Actavis Recent Developments
    Table 113. Chugai Pharmaceutical Company Information
    Table 114. Chugai Pharmaceutical Description and Major Businesses
    Table 115. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 116. Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Chugai Pharmaceutical Recent Developments
    Table 118. Ferring International Center Company Information
    Table 119. Ferring International Center Description and Major Businesses
    Table 120. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 121. Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Ferring International Center Recent Developments
    Table 123. Synergy Pharmaceuticals Company Information
    Table 124. Synergy Pharmaceuticals Description and Major Businesses
    Table 125. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 126. Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Synergy Pharmaceuticals Recent Developments
    Table 128. Pfizer Company Information
    Table 129. Pfizer Description and Major Businesses
    Table 130. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 131. Pfizer Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Pfizer Recent Developments
    Table 133. GlaxoSmithKline Company Information
    Table 134. GlaxoSmithKline Description and Major Businesses
    Table 135. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 136. GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. GlaxoSmithKline Recent Developments
    Table 138. Roche Holding Company Information
    Table 139. Roche Holding Description and Major Businesses
    Table 140. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 141. Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. Roche Holding Recent Developments
    Table 143. Sanofi Company Information
    Table 144. Sanofi Description and Major Businesses
    Table 145. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 146. Sanofi Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. Sanofi Recent Developments
    Table 148. Bayer Company Information
    Table 149. Bayer Description and Major Businesses
    Table 150. Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 151. Bayer Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. Bayer Recent Developments
    Table 153. Salix Pharmaceuticals Company Information
    Table 154. Salix Pharmaceuticals Description and Major Businesses
    Table 155. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 156. Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 157. Salix Pharmaceuticals Recent Developments
    Table 158. Sucampo Pharmaceuticals Company Information
    Table 159. Sucampo Pharmaceuticals Description and Major Businesses
    Table 160. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 161. Sucampo Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 162. Sucampo Pharmaceuticals Recent Developments
    Table 163. Ironwood Pharmaceuticals Company Information
    Table 164. Ironwood Pharmaceuticals Description and Major Businesses
    Table 165. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 166. Ironwood Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 167. Ironwood Pharmaceuticals Recent Developments
    Table 168. Progenics Pharmaceuticals Company Information
    Table 169. Progenics Pharmaceuticals Description and Major Businesses
    Table 170. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 171. Progenics Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 172. Progenics Pharmaceuticals Recent Developments
    Table 173. Key Raw Materials Lists
    Table 174. Raw Materials Key Suppliers Lists
    Table 175. Chronic Idiopathic Constipation (CIC) Drugs Distributors List
    Table 176. Chronic Idiopathic Constipation (CIC) Drugs Customers List
    Table 177. Chronic Idiopathic Constipation (CIC) Drugs Market Trends
    Table 178. Chronic Idiopathic Constipation (CIC) Drugs Market Drivers
    Table 179. Chronic Idiopathic Constipation (CIC) Drugs Market Challenges
    Table 180. Chronic Idiopathic Constipation (CIC) Drugs Market Restraints
    Table 181. Research Programs/Design for This Report
    Table 182. Key Data Information from Secondary Sources
    Table 183. Key Data Information from Primary Sources
List of Figures
    Figure 1. Chronic Idiopathic Constipation (CIC) Drugs Product Picture
    Figure 2. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Chronic Idiopathic Constipation (CIC) Drugs Market Share by Type in 2023 & 2030
    Figure 4. Lubiprostone Product Picture
    Figure 5. Linaclotide Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Chronic Idiopathic Constipation (CIC) Drugs Market Share by Application in 2023 & 2030
    Figure 9. Hospitals & Clinics
    Figure 10. Ambulatory Surgical Centres
    Figure 11. Long Term Care Centres
    Figure 12. Others
    Figure 13. Chronic Idiopathic Constipation (CIC) Drugs Report Years Considered
    Figure 14. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue 2019-2030 (US$ Million)
    Figure 16. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 17. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Region (2019-2030)
    Figure 18. Global Chronic Idiopathic Constipation (CIC) Drugs Sales 2019-2030 ((K Units)
    Figure 19. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Region (2019-2030)
    Figure 20. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales YoY (2019-2030) & (K Units)
    Figure 21. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales YoY (2019-2030) & (K Units)
    Figure 23. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. China Chronic Idiopathic Constipation (CIC) Drugs Sales YoY (2019-2030) & (K Units)
    Figure 25. China Chronic Idiopathic Constipation (CIC) Drugs Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Asia (excluding China) Chronic Idiopathic Constipation (CIC) Drugs Sales YoY (2019-2030) & (K Units)
    Figure 27. Asia (excluding China) Chronic Idiopathic Constipation (CIC) Drugs Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales YoY (2019-2030) & (K Units)
    Figure 29. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue YoY (2019-2030) & (US$ Million)
    Figure 30. The Chronic Idiopathic Constipation (CIC) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 31. The Top 5 and 10 Largest Manufacturers of Chronic Idiopathic Constipation (CIC) Drugs in the World: Market Share by Chronic Idiopathic Constipation (CIC) Drugs Revenue in 2023
    Figure 32. Global Chronic Idiopathic Constipation (CIC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 33. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 34. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 35. Global Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 36. Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 37. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 38. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 39. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 40. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 41. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Country (2019-2030)
    Figure 42. US & Canada Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Country (2019-2030)
    Figure 43. U.S. Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 44. Canada Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 45. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 46. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 47. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 48. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 49. Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Country (2019-2030)
    Figure 50. Europe Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Country (2019-2030)
    Figure 51. Germany Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 52. France Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 53. U.K. Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 54. Italy Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 55. Russia Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 56. China Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 57. China Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 58. China Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 59. China Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 60. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 61. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 62. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 63. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 64. Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Region (2019-2030)
    Figure 65. Asia Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Region (2019-2030)
    Figure 66. Japan Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 67. South Korea Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 68. China Taiwan Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 69. Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 70. India Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 71. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Type (2019-2030)
    Figure 72. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Type (2019-2030)
    Figure 73. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Application (2019-2030)
    Figure 74. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue Market Share by Application (2019-2030)
    Figure 75. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Country (2019-2030)
    Figure 76. Middle East, Africa and Latin America Chronic Idiopathic Constipation (CIC) Drugs Sales Share by Country (2019-2030)
    Figure 77. Brazil Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 78. Mexico Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 79. Turkey Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 80. Israel Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 81. GCC Countries Chronic Idiopathic Constipation (CIC) Drugs Revenue (2019-2030) & (US$ Million)
    Figure 82. Chronic Idiopathic Constipation (CIC) Drugs Value Chain
    Figure 83. Chronic Idiopathic Constipation (CIC) Drugs Production Process
    Figure 84. Channels of Distribution
    Figure 85. Distributors Profiles
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed